Key clinical point: Long-term data point to the efficacy and safety of chemotherapy-free, first-line treatment of indolent lymphoma.
Major finding: After a median of 10.6 years’ follow up, 73% of patients were alive, and 36% did not require chemotherapy.
Study details: Ten-year follow-up data from two trials on 321 previously untreated patients who had follicular lymphoma, marginal zone lymphoma, small lymphocytic lymphoma, or indolent lymphoma not otherwise specified.
Disclosures: The study was funded in part by the Stockholm County Council and by the Nordic Lymphoma Group. The trials analyzed in the study were supported by Roche. Dr. Lockmer reported having no financial disclosures. Her coauthors reported relationships with Novartis, Gilead, Roche, and Takeda, among others.
Lockmer S et al. J Clin Oncol. 2018 Oct 4:JCO1800262. doi: 10.1200/JCO.18.00262.
This Week's Must Reads
Oncologists raise access concerns about new mobile technology, Article based on interviews.
Broad opioid legislation advances in Congress, Senate floor debate, Sept. 17, 2018
Early supportive care cuts costs related to curative treatment, Koprowski CD et al. 2018 ASCO Quality Care Symposium, Abstract 142
Employee deductibles outstrip wages, Kaiser Family Foundation, 2018 Employer Health Benefits
The financial burden of metastatic breast cancer, Wheeler SB et al. Quality Care Symposium, Abstract 32
Must Reads in Lymphoma & Plasma Cell Disorders
Long-term data on chemo-free approach in advanced indolent lymphoma, Lockmer S et al. J Clin Oncol. 2018 Oct 4:JCO1800262. doi: 10.1200/JCO.18.00262
Race and pruritus create cancer risk picture, Kwatra SG et al. J Am Acad Dermatol. 2018 Sep 11. doi: 10.1016/j.jaad.2018.08.044.
Adding Bv improved survival for some Hodgkin patients, Evens AM et al. J Clin Oncol. 2018 Sep 4. doi: 10.1200/JCO.2018.79.0139.
First-line chemo-free MCL combo is durable, Ruan J et al. Blood. 2018 Sep 4. doi: 10.1182/blood-2018-07-859769.
Long-term ibrutinib data in older patients, Barr PM et al. Haematologica. 2018;103(9):1502-10